Stockscreener 앱 받기
8.18
2.12%
0.17
시간 외 거래:
8.25
0.07
+0.86%
전일 마감가:
$8.01
열려 있는:
$7.865
하루 거래량:
1.39M
Relative Volume:
0.76
시가총액:
$1.06B
수익:
$727.33M
순이익/손실:
$-108.03M
주가수익비율:
-9.6919
EPS:
-0.844
순현금흐름:
$-21.78M
1주 성능:
+2.51%
1개월 성능:
-18.28%
6개월 성능:
-3.99%
1년 성능:
-17.79%
1일 변동 폭
$7.85
$8.225
1주일 범위
$7.85
$8.515
52주 변동 폭
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.18 | 1.04B | 727.33M | -108.03M | -21.78M | -0.844 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-29 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 개시 | Guggenheim | Neutral |
| 2025-04-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
NeoGenomics (NEO) launches RaDaR ST to capture share in $20B MRD market - MSN
NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market - Insider Monkey
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
NeoGenomics, Inc. (NASDAQ: NEO) Q4 2025 earnings call transcript - MSN
11 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
NeoGenomics offers preview of booth presence at USCAP2026 - Traders Union
NeoGenomics Beats Investor Suit Over Growth Driver Claims - Law360
Will Medicare Coverage for PanTracer LBx Liquid Biopsy Shift NeoGenomics' (NEO) Diagnostic Narrative? - Yahoo Finance
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges - Markets Mojo
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - simplywall.st
NeoGenomics’ PanTracer LBx test receives Medicare coverage By Investing.com - Investing.com South Africa
NEO NeoGenomics, Inc. Maintained: Cowen Buy, William Blair Market Perform Mar 2026 - Meyka
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit - Bloomberg Law News
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling - BioSpace
William Blair reiterates Market Perform on Neogenomics stock after Medicare coverage decision - Investing.com
Neogenomics stock gets Medicare coverage for blood-based test By Investing.com - Investing.com Canada
Neogenomics stock gets Medicare coverage for blood-based test - Investing.com
NeoGenomics test gains Medicare coverage for cancer care - Gulfshore Business
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biop - pharmiweb.com
Neogenomics stock gets MolDX reimbursement for cancer test - Investing.com
Neogenomics IncPantracer Lbx Test Receives Medicare Coverage Under CMS Moldx Program - TradingView
NeoGenomics’ PanTracer LBx test receives Medicare coverage - Investing.com
NeoGenomics, Inc. $NEO Stock Position Increased by First Light Asset Management LLC - MarketBeat
Silverback Asset Management LLC Invests $1.55 Million in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics to present at NextGen Omics Spatial and Data U.S. 2026 on immunotherapy resistance mapping - Traders Union
Liquid Biopsy Market to Reach US$28.20 Billion by 2033 at 12.8% - openPR.com
NeoGenomics (NEO) Price Target Increased by 21.45% to 12.44 - MSN
NeoGenomics announces launch of new cancer assay PanTracer Pro - MSN
Trend Review: Can NeoGenomics Inc keep up with sector leadersQuarterly Trade Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
NeoGenomics (NASDAQ:NEO) Stock Price Down 7.9%Should You Sell? - MarketBeat
Greenhouse Funds LLLP Acquires 789,510 Shares of NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics at Leerink Conference: Strategic Growth Focus By Investing.com - Investing.com India
NeoGenomics at Leerink Conference: Strategic Growth Focus - Investing.com
Investment Recap: Is NeoGenomics Inc gaining market share2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Insider Sell: Can NeoGenomics Inc deliver alphaMarket Activity Report & Expert Verified Movement Alerts - baoquankhu1.vn
NeoGenomics Q4 2025 earnings preview - MSN
GW&K Investment Management LLC Cuts Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
Royce & Associates LP Sells 860,000 Shares of NeoGenomics, Inc. $NEO - MarketBeat
Vanguard Group Inc. Has $107.34 Million Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. $NEO Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
NeoGenomics (NEO) accounting chief granted new options and RSUs - Stock Titan
Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay - Stock Titan
NeoGenomics (NEO) COO receives new stock option and RSU grants - Stock Titan
Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook - Stock Titan
NeoGenomics at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
NeoGenomics at TD Cowen Conference: Strategic Growth Insights - Investing.com South Africa
A Look At NeoGenomics (NEO) Valuation After The RaDaR ST Assay Launch - simplywall.st
NeoGenomics Stock Price Drops Below 200-Day Average - National Today
NeoGenomics (NASDAQ:NEO) Stock Price Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs - Stock Titan
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):